Oral tablet form: Began a Phase I/II dose-escalation trial

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: Oral tablet form of GS 840, a prodrug that is converted in the body to GS 393, a nucleotide analog inhibitor of reverse transcriptase Indicat...